Log In
Print
BCIQ
Print
Print this Print this
 

Epanova

  Manage Alerts
Collapse Summary General Information
Company Chrysalis Pharma AG
DescriptionUltra-pure mixture of the free fatty acid forms of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)
Molecular Target
Mechanism of Action 
Therapeutic ModalityMacromolecule: Fatty acid/lipid
Latest Stage of DevelopmentApproved
Standard IndicationHypertriglyceridemia
Indication DetailsTreat hypertriglyceridemia; Treat severe hypertriglyceridemia
Regulatory Designation

U.S. - Special Protocol Assessment (Treat hypertriglyceridemia);
U.S. - Standard Review (Treat severe hypertriglyceridemia)

Partner

AstraZeneca plc


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$443.0M

$323.0M

$120.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today